Mixing study demonstrating the superior resolution of miRAMM as compared with serum protein electrophoresis and IFE for distinguishing and quantitating M-proteins in the presence of daratumumab. Residual patient sera with an endogenous M-protein comigrating with daratumumab was mixed with different concentrations of daratumumab to achieve a 0.3 g/dL final concentrations with the following compositions: 0.27 g/dL daratumumab and 0.03 g/dL comigrating M-protein, 0.15 g/dL daratumumab and 0.15 g/dL comigrating M-protein, and 0.03 g/dL daratumumab and 0.27 g/dL of comigrating M-protein.